作者：
Sebastian,Schmid [1]
;
Zachary R,Russell [1]
;
Alex Shimura,Yamashita [2]
;
Madeline E,West [1]
;
Abigail G,Parrish [1]
;
Julia,Walker [1]
;
Dmytro,Rudoy [1]
;
James Z,Yan [1]
;
David C,Quist [1]
;
Betemariyam N,Gessesse [1]
;
Neriah,Alvinez [1]
;
Kimberly D,Hill [3]
;
Larry W,Anderson [3]
;
Patrick J,Cimino [4]
;
Debra K,Kumasaka [1]
;
Ralph E,Parchment [2]
;
Eric C,Holland [5]
;
Frank,Szulzewsky [6]
作者单位：
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
[1]
Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USA.
[2]
Pharmacokinetics Laboratory, Developmental Therapeutics Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
[3]
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
[4]
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Seattle Translational Tumor Research Center, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
[5]
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: frank.szulzewsky@hsc.utah.edu.
[6]
主题词
动物(Animals);神经胶质瘤(Glioma);蛋白激酶抑制剂(Protein Kinase Inhibitors);小鼠(Mice);疾病模型, 动物(Disease Models, Animal);MAP激酶信号系统(MAP Kinase Signaling System);受体, trkA(Receptor, trkA);人类(Humans);抗药性, 肿瘤(Drug Resistance, Neoplasm);癌基因蛋白质类, 融合(Oncogene Proteins, Fusion);受体, trkC(Receptor, trkC);受体, trkB(Receptor, trkB)
DOI
10.1016/j.celrep.2024.114829
PMID
39365700
发布时间
2025-01-23
换一批
换一批
